• OPEN AN ACCOUNT
Indian Indices
Sensex
83,277.15 650.39
( 0.79%)
Global Indices
Nasdaq
49,514.94 41.95
(0.08%)
Dow Jones
6,856.39 2.63
(0.04%)
Hang Seng
56,974.47 32.50
(0.06%)
Nikkei 225
10,448.94 46.50
(0.45%)
Forex
USD-INR
90.59 -0.07
(-0.07%)
EUR-INR
107.56 -0.26
(-0.24%)
GBP-INR
123.48 -0.32
(-0.26%)
JPY-INR
0.59 0.00
(0.20%)

EQUITY - MARKET SCREENER

Morganite Crucible (India) Ltd
Industry :  Refractories / Intermediates
BSE Code
ISIN Demat
Book Value()
523160
INE599F01020
241.9683929
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
32.68
808.67
EPS(TTM)
Face Value()
Div & Yield %
44.19
5
3.39
 

Astrazeneca Pharma and Sun Pharma form second brand partnership
Nov 17,2025
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.